Knowledge Hub

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

Press release   •   Jul 18, 2016 07:18 EDT

Global Markets Directs, Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

The report provides comprehensive information on the Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/726756

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)

- The report reviews Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company andindustry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Latest News at http://www.marketresearchreports.biz/articles

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Overview 10

Therapeutics Development 11

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Stage of Development 11

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Therapy Area 12

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Indication 13

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Companies 17

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Universities/Institutes 23

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Therapeutics Assessment 25

Assessment by Monotherapy/Combination Products 25

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Companies Involved in Therapeutics Development 32

Advaxis, Inc. 32

American Gene Technologies International Inc. 33

Aprea AB 34

Cellceutix Corporation 35

Critical Outcome Technologies Inc. 36

Eleos Inc. 37

ORCA Therapeutics B.V. 38

OSE Pharma SA 39

PCI Biotech Holding ASA 40

Quark Pharmaceuticals, Inc. 41

Stemline Therapeutics, Inc. 42

Shenzen SiBiono GeneTech Co., Ltd. 43

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.